Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prevalence of HCV Among Baby Boomers in US

J Infect Public Health; ePub 2018 Aug 28; Moore, et al

Baby boomers (BB) had the highest prevalence of hepatitis C virus (HCV) infection among the US population, and it’s important for healthcare professionals to identify age-specific risk factors in this group and use them in targeted screening and public health prevention efforts. This according to a recent study that examined US adult HCV prevalence and age-specific risk factors for chronic HCV infection. Researchers analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 1999-2012. Age was divided into 3 categories: BB, younger than BB (YG), and older than BB (OG). They found:

  • Overall prevalence of chronic HCV was 1.19% with a US population estimate of 2,347,852 US adults.
  • BB had the highest prevalence at 2.23%, accounting for >74% of all chronic HCV cases.
  • HCV prevalence was highest among all ages (1.83%) and BB (2.71%) in 2001-2002.
  • Among BB, males, non-Hispanic blacks, having positive blood transfusion history, current and former smokers, and living below the poverty level were significant predictors of chronic HCV positivity.

Citation:

Moore KJ, Gauri A, Koru-Sengul T. Prevalence and sociodemographic disparities of hepatitis C in Baby Boomers and the US adult population. [Published online ahead of print August 28, 2018]. J Infect Public Health. doi:10.1016/j.jiph.2018.08.003.

This Week's Must Reads

Intensive BP Control & Risk of Dementia, JAMA; ePub 2019 Jan 28; SPRINT MIND Investigators

Outpatient Care for Adults With Primary Care, JAMA Intern Med; ePub 2019 Jan 28; Levine, et al

Antibiotic Therapy in Patients with Asthma, JAMA Intern Med; ePub 2019 Jan 28; Stefan, et al

Outpatient Benzodiazepine Prescribing in US, JAMA Netw Open; 2019 Jan 25; Agarwal, et al

Reduction of Readmissions Through Primary Care, JAMA Netw Open; 2019 Jan 25; Wiest, et al

Must Reads in Hepatitis

Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al

HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al

HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al

Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al

Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al